| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Departments of Neurology (Drs. Mason and DeAngelis) and Radiology (Dr. Krol), Memorial Sloan-Kettering Cancer Center, and the Department of Neurology and Neuroscience (Drs. Mason and DeAngelis), Cornell University Medical College, New York, NY.
Presented in part at the 46th annual meeting of the American Academy of Neurology, Washington, DC, May 1994.
Received February 27, 1995. Accepted in final form April 18, 1995.
Address correspondence and reprint requests to Dr. Lisa M. DeAngelis, Department of Neurology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021.
Article abstract-We administered chemotherapy in standard and intensified formulations of procarbazine, lomustine (CCNU), and vincristine to nine symptomatic patients with low-grade oligodendroglioma. Eight patients were treated with chemotherapy at presentation and one was treated for a recurrence after radiotherapy had failed. All patients improved by clinical or MRI criteria, or both. No patient deteriorated while in therapy and the responses were sustained without radiotherapy for a median of 35 months (range, 22-45) in all surviving patients treated at presentation. Chemotherapy was well tolerated; all patients developed myelosuppression, but only those receiving the intensified regimen required dose reduction or premature discontinuation of treatment. As with recurrent and anaplastic oligodendroglioma, low-grade oligodendroglioma responds to chemotherapy.
NEUROLOGY 1996;46: 203-207
This article has been cited by other articles:
|
|
 |
|
  S. Kesari, D. Schiff, J. Drappatz, D. LaFrankie, L. Doherty, E. A. Macklin, A. Muzikansky, S. Santagata, K. L. Ligon, A. D. Norden, et al. Phase II Study of Protracted Daily Temozolomide for Low-Grade Gliomas in Adults Clin. Cancer Res., January 1, 2009; 15(1): 330 - 337. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Schiff, P. D. Brown, and C. Giannini Outcome in adult low-grade glioma: The impact of prognostic factors and treatment Neurology, September 25, 2007; 69(13): 1366 - 1373. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Grier and T. Batchelor Low-grade gliomas in adults. Oncologist, June 1, 2006; 11(6): 681 - 693. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. E. Abrey, B. H. Childs, N. Paleologos, L. Kaminer, S. Rosenfeld, D. Salzman, J. L. Finlay, S. Gardner, K. Peterson, W. Hu, et al. High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: Long-term follow-up Neuro-oncol, April 1, 2006; 8(2): 183 - 188. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. F. Lang and M. R. Gilbert Diffusely Infiltrative Low-Grade Gliomas in Adults J. Clin. Oncol., March 10, 2006; 24(8): 1236 - 1245. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. K. Koeller and E. J. Rushing From the Archives of the AFIP: Oligodendroglioma and Its Variants: Radiologic-Pathologic Correlation RadioGraphics, November 1, 2005; 25(6): 1669 - 1688. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Higuchi, Y. Iwadate, and A. Yamaura Treatment of low-grade oligodendroglial tumors without radiotherapy Neurology, December 28, 2004; 63(12): 2384 - 2386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hoang-Xuan, L. Capelle, M. Kujas, S. Taillibert, H. Duffau, J. Lejeune, M. Polivka, E. Criniere, Y. Marie, K. Mokhtari, et al. Temozolomide As Initial Treatment for Adults With Low-Grade Oligodendrogliomas or Oligoastrocytomas and Correlation With Chromosome 1p Deletions J. Clin. Oncol., August 1, 2004; 22(15): 3133 - 3138. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sanson, S. Cartalat-Carel, S. Taillibert, M. Napolitano, L. Djafari, J. Cougnard, H. Gervais, F. Laigle, A. Carpentier, K. Mokhtari, et al. Initial chemotherapy in gliomatosis cerebri Neurology, July 27, 2004; 63(2): 270 - 275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Lebrun, D. Fontaine, A. Ramaioli, F. Vandenbos, S. Chanalet, M. Lonjon, J. F. Michiels, V. Bourg, P. Paquis, M. Chatel, et al. Long-term outcome of oligodendrogliomas Neurology, May 25, 2004; 62(10): 1783 - 1787. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Brada, L. Viviers, C. Abson, F. Hines, J. Britton, S. Ashley, S. Sardell, D. Traish, A. Gonsalves, P. Wilkins, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas Ann. Onc., December 1, 2003; 14(12): 1715 - 1721. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Pace, A. Vidiri, E. Galie, M. Carosi, S. Telera, A. M. Cianciulli, P. Canalini, D. Giannarelli, B. Jandolo, and C. M. Carapella Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response Ann. Onc., December 1, 2003; 14(12): 1722 - 1726. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. D. Brown, J. T. Wald, M. W. McDermott, G. S. Baumann, and T. F. Cloughesy Oncodiagnosis panel: 2002. Optic nerve glioma or optic nerve meningioma. RadioGraphics, November 1, 2003; 23(6): 1591 - 1611. [Full Text] [PDF]
|
|
|
|
|
|
D. Schiff and M. Sanson Dramatic response to chemotherapy in oligodendroglial gliomatosis cerebri Neurology, August 12, 2003; 61(3): 425 - 425. [Full Text] [PDF]
|
|
|
|
|
|
M. van den Bent, O.-L. Chinot, and J. G. Cairncross Recent developments in the molecular characterization and treatment of oligodendroglial tumors Neuro-oncol, April 1, 2003; 5(2): 128 - 138. [Abstract] [PDF]
|
|
|
|
|
|
J. A. Quinn, D. A. Reardon, A. H. Friedman, J. N. Rich, J. H. Sampson, J. M. Provenzale, R. E. McLendon, S. Gururangan, D. D. Bigner, J. E. Herndon II, et al. Phase II Trial of Temozolomide in Patients With Progressive Low-Grade Glioma J. Clin. Oncol., February 15, 2003; 21(4): 646 - 651. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Buckner, D. Gesme Jr, J. R. O'Fallon, J. E. Hammack, S. Stafford, P. D. Brown, R. Hawkins, B. W. Scheithauer, B. J. Erickson, R. Levitt, et al. Phase II Trial of Procarbazine, Lomustine, and Vincristine as Initial Therapy for Patients With Low-Grade Oligodendroglioma or Oligoastrocytoma: Efficacy and Associations With Chromosomal Abnormalities J. Clin. Oncol., January 15, 2003; 21(2): 251 - 255. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Shaw, R. Arusell, B. Scheithauer, J. O'Fallon, B. O'Neill, R. Dinapoli, D. Nelson, J. Earle, C. Jones, T. Cascino, et al. Prospective Randomized Trial of Low- Versus High-Dose Radiation Therapy in Adults With Supratentorial Low-Grade Glioma: Initial Report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group Study J. Clin. Oncol., May 1, 2002; 20(9): 2267 - 2276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Peterson and L. M. DeAngelis Weighing the benefits and risks of radiation therapy for low-grade glioma Neurology, May 22, 2001; 56(10): 1255 - 1256. [Full Text] [PDF]
|
|
|
|
|
|
O.-L. Chinot, S. Honore, H. Dufour, M. Barrie, D. Figarella-Branger, X. Muracciole, D. Braguer, P.-M. Martin, and F. Grisoli Safety and Efficacy of Temozolomide in Patients With Recurrent Anaplastic Oligodendrogliomas After Standard Radiotherapy and Chemotherapy J. Clin. Oncol., May 1, 2001; 19(9): 2449 - 2455. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. DeAngelis Brain Tumors N. Engl. J. Med., January 11, 2001; 344(2): 114 - 123. [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Nutt, M. Noble, A. F. Chambers, and J. G. Cairncross Differential Expression of Drug Resistance Genes and Chemosensitivity in Glial Cell Lineages Correlate with Differential Response of Oligodendrogliomas and Astrocytomas to Chemotherapy Cancer Res., September 1, 2000; 60(17): 4812 - 4818. [Abstract] [Full Text]
|
|
|
|
|
|
J. D. Olson, E. Riedel, and L. M. DeAngelis Long-term outcome of low-grade oligodendroglioma and mixed glioma Neurology, April 11, 2000; 54(7): 1442 - 1448. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Cairncross, L. Swinnen, R. Bayer, S. Rosenfeld, D. Salzman, N. Paleologos, L. Kaminer, P. Forsyth, D. Stewart, K. Peterson, et al. Myeloablative chemotherapy for recurrent aggressive oligodendroglioma Neuro-oncol, April 1, 2000; 2(2): 114 - 119. [Abstract] [PDF]
|
|
|
|
|
|
J. S. Smith, A. Perry, T. J. Borell, H. K. Lee, J. O’Fallon, S. M. Hosek, D. Kimmel, A. Yates, P. C. Burger, B. W. Scheithauer, et al. Alterations of Chromosome Arms 1p and 19q as Predictors of Survival in Oligodendrogliomas, Astrocytomas, and Mixed Oligoastrocytomas J. Clin. Oncol., February 1, 2000; 18(3): 636 - 636. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Perry, D. N. Louis, and J. G. Cairncross Current Treatment of Oligodendrogliomas Arch Neurol, April 1, 1999; 56(4): 434 - 436. [Full Text] [PDF]
|
|
|
|
|
|
N. A. Paleologos and J. G. Cairncross Treatment of oligodendroglioma: An update Neuro-oncol, January 1, 1999; 1(1): 61 - 68. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
